Amgen Gets Exit At Adheron Therapeutics

Thousand Oaks-based Amgen has seen an exit out of its startup investment portfolio, and activities of its Amgen Ventures venture capital arm, at Berkeley-based Adheron Therapeutics this morning. Adheron said that it has been acquired by Roche, in a deal worth $105M upfront and up to $475M in additional milestone payments. Adheron is developing technology that disrupts immune cell adhesion, which is being applied to treatments for inflammatory and autoimmune diseases, including rheumatoid arthritis. In addition to Amgen, Adheron has received venture capital from Health Care Ventures, MedImmune Ventures, Partners Innovation Fund, and SROne.